Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Surg Oncol Clin N Am. 2011 Jan;20(1):79–103. doi: 10.1016/j.soc.2010.09.008

Table 1.

Response rates following melphalan-based HILP and ILI in patients with melanoma.

Study N CR (%) PR (%) SD (%) PD (%) Condition
HILP Minor 198513 18 82 18 0 0 Hyperthermia
Storm 198514 26 50 31 19* 0 Hyperthermia
Kroon 198715 18 38 44 17* 0 Normothermia
Kroon 199316 43 77 14 9* 0 Normothermia
Klaase 199417 120 54 25 21* 0 Normothermia
Grünhagen 200418 100 69 26 5* 0 Hyperthermia
Aloia 200519 59 57 31 12* 0 Hyperthermia
Cornett 200620 58 25 39 28 11 Hyperthermia
Sanki 200721 120 69 16 0 15 Hyperthermia
ILI Mian 200122 9 44 56 0 0
Lindner 200223 128 41 44 12 4
Bonenkamp 200424 13 31 61 0 8
Brady 200625** 22 23 27 0 50
Beasley 200830 50 30 14 10 46
Kroon 200826*** 185 38 46 10 6
Beasley 200927 128 31 33 7 29

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

*

No response.

**

Includes one patient with advanced sarcoma.

***

Includes 128 patients reviewed in Lindner 2002.